Loading company
ONCBeone Medicines Ltd.$48BA+Built from Arrivent Biopharma, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Arrivent Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$13.520.0%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Just reported
From Arrivent Biopharma's results release of November 9, 2026; its quarterly report has since been filed.
Actual
$5M
Guided
—
No guide given
Actual
-$0.81
Guided
—
No guide given
Actual
-$43.4M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Not rated
The band under the price shows the grade on each date, built only from filings that were public by then.
There is no grade history to chart for Arrivent Biopharma, Inc. yet. The quarterly grade is rebuilt from only the filings that were public at the time, and this company has not yet reported enough of them to score a single quarter.
